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The Editor 
Nutritional Neuroscience 
 
Dear Editor, 
 
Re: THE NEUROPROTECTIVE EFFECTS OF AN ETHANOLIC TURMERIC 
(Curcuma longa L.) EXTRACT AGAINST TRIMETHYLTIN-INDUCED OXIDATIVE 
STRESS IN RATS 
By Sapto Yuliani, Mustofa, and Ginus Partadiredja 
 We would like to express our gratitude to the editor and the reviewers for their comments 
on our manuscript in your email dated 31 January 2018. We also would like to thank the editor 
for giving us chances to improve our manuscript and thus to make it suitable for publication in 
the Nutritional Neuroscience journal. Please find our responses to the comments of the reviewer 
below and how we have improved our manuscript accordingly (additional sentences written in 
red): 
 
Reviewer #1:  
1. In the method section of the abstract please state the experimental design in more detail.  
There were six groups....., etc.  Please list the doses of turmeric extract that were dministered. 
  
Our response: We comply with the reviewer request. We have added more detailed information 
of the experimental design in the abstract. 
 
2. The experimental design includes administration of turmeric extract before and after 
administration of trimethyltin. Since, in most cases, prophylactic treatment cannot be 
administered for neurodegenerative disorders because treatment starts after the disorder is 
Response to reviewer comments
diagnosed, the strongest experimental design would be to administer the insult that produces 
neurodegeneration and then administer the treatment to see if neurodegeneration could be halted 
or reversed. However, the study design used does shown an effect on the oxidative stress 
markers in the brain.  It is not clear if it is a protective effect or a treatment effect. In several 
places the discussion refers to the effect as protective. Please clarify the language to be consistent 
with the study design. 
  
Our response: We have added an explanation on this preventive issue in paragraph 2 of the 
discussion section. It is true that the design of the experiment was for preventive. 
 
 3. The results show that turmeric has activity similar to the positive control at a dose of 200 
mg/kg but not at 100 or 300 mg/kg.  Is there a reason those 3 doses were chosen?  If so, please 
include that information. 
 
Our response: We have added the information about the reason and the reference for using the 
doses in the experimental design sub-section of the methods. 
 
Inverted U curves are not uncommon in pharmacology studies and they usually represent some 
change in pharmacological activity as the concentration of test material at the receptor changes. 
Do you know what receptors or other targets turmeric might act on to alter oxidative stress?  If 
so, it would be helpful to discuss a possible mechanism in the discussion, which could lead to 
further, more mechanistic studies. 
 
Our response: We have added an explanation about this matter in the paragraph 3 of the 
discussion section. 
 
 4. The discussion suggests that the new formulation of turmeric may be less bioavailable.  If 
possible, addition of PK data from plasma and brain tissue would strengthen the paper. If not 
possible for this study, please consider it for future studies. 
 
Our response: We thank the reviewer for the important suggestion of incorporating PK data 
from plasma and brain tissue. However, it is not possible to be conducted at present since this 
study has been accomplished. Nevertheless, we have included the suggestion in the last sentence 
of paragraph 5 of the discussion section. 
  
 5. Please check for misspellings and typos. Page 14, third line from top, "oxygen" is spelled 
"oxygen". 
 
Our response: We have made the correction of "oxigen” into “oxygen” 
Once again, we thank the editor and reviewer for giving us positive comments, and therefore 
enabling us to improve our manuscript to be suitable for publication in the Nutritional 
Neuroscience journal. Please find the attached file where we have made amendments 
accordingly. 
Yours sincerely, 
 Ginus Partadiredja 
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THE NEUROPROTECTIVE EFFECTS OF AN ETHANOLIC TURMERIC (Curcuma 
longa L.) EXTRACT AGAINST TRIMETHYLTIN-INDUCED OXIDATIVE STRESS IN 
RATS 
 
ABSTRACT 
Introduction: Oxidative stress is known to contribute to the pathogenesis of neurodegenerative 
disorders. An ethanolic turmeric (Curcuma longa L.) extract containing curcumin has been 
reported to produce antioxidant effects.  
Objective: The present study aims to investigate the possible neuroprotective effects of the 
ethanolic turmeric extract against trimethyltin (TMT)-induced oxidative stress in Sprague 
Dawley rats.  
Methods: Rats were divided randomly into six groups, i.e. N group, which served as a normal 
control group; T group, which was given intra-peritoneal injection of TMT chloride; T-Cit 
group, which was treated with oral citicoline and TMT chloride injection; and three turmeric-
treated groups (T-TE100, T-TE200, T-TE300) which were given 100, 200 and 300 mg/kg bw of 
turmeric rhizome extract orally, as well as TMT chloride. The treatments were administered to 
the TMT-exposed rats from day 1 to day 28 of the experiment. The TMT chloride injection was 
administered as a single dose of 8 mg/kg bw on day 8 of the experiment.  The plasma and brain 
malondialdehyde (MDA) levels and reduced glutathione (GSH) levels and the activities of the 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) enzymes in the 
brain were examined at the end of the experiment.  
Results: The TMT injection resulted in a significant increase in the plasma and brain MDA 
levels and a decrease in the SOD, CAT, and GPx enzyme activities as well as GSH levels in the 
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2 
 
brain. The administration of 200 mg/kg bw of the ethanolic turmeric extract prevented oxidative 
stress by decreasing the plasma and brain MDA levels and increasing the SOD, CAT, and GPx 
enzyme activities and GSH levels in the brain. These effects seem to be comparable to those of 
citicoline.  
Discussion: The ethanolic turmeric extract at a dose of 200 mg/kg bw may exert neuroprotective 
effects on TMT-exposed Sprague Dawley rats by preventing them from oxidative stress. 
 
Keywords: neurodegeneration; Curcuma longa L.; trimethyltin; oxidative stress; antioxidant 
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1. Introduction 
 Oxidative stress, which is an imbalance between reactive oxygen species production and 
elimination by the antioxidant defense system, is considered to underpin the pathogenesis of 
neurodegenerative disorders [1]. Brain cells are very sensitive to oxidative damage, due to the 
high oxygen demand of the brain. Oxidative damage to lipids consisting of unsaturated fatty 
acids (lipid peroxidation) yields end products such as malondialdehyde (MDA), 4-hydroxy-2,3-
nonenal (HNE), acrolein, and other compounds [2] that exert negative effects on human health. 
 Endogenous antioxidant enzymes, such as glutathione peroxidase (GPx), superoxide 
dismutase (SOD) and catalase (CAT), serve to protect the cells from the oxidative damage [3]. 
However, while the unsaturated fatty acid content of the brain is high, the antioxidant defense 
system of the brain is weaker compared to that of other organs. Therefore, oxidative stress may 
easily cause the degeneration of the hippocampus, a major brain region for memory processing. 
In turn, such degeneration may play a role in the pathogenesis of neurodegenerative disorders, 
including dementia [4].  
 Trimethyltin (TMT) is an organometal that has neurotoxic effects. TMT enhances the 
formation of reactive oxygen species in the hippocampus. TMT also increases the expression of 
important factors related to the pathophysiology of Alzheimer’s disease (AD) such as amyloid 
precursor protein (APP), presenilin and c-fos  in the limbic system [5]. Therefore, TMT-
intoxicated rats may serve as valuable models for studies of neurodegenerative disorders, such as 
Alzheimer’s disesase [6].  
 Curcuma longa, L. or turmeric is widely known as a dietary food ingredient and 
traditionally used as a medicinal herb. The potential use of turmeric as an alternative medicine is 
attributed to its antioxidant properties. In vitro and in vivo studies showed that the active 
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compound of turmeric extract, curcumin,  prevented oxidative stress-induced neurodegeneration 
in the nervous system [7,8]. Our previous studies have shown that an ethanolic turmeric extract 
prevented the deficits of the spatial memory and the estimated total number of hippocampal 
pyramidal cells [9], as well as inhibited the apoptosis of the pyramidal neurons in the CA2-CA3 
region, but not in the CA1 region of the hippocampus of TMT-exposed rats [10]. The present 
study extends these studies and aims to determine the effects of the ethanolic extract of turmeric 
on the levels of oxidative stress markers in the brains and plasma of Sprague Dawley rats 
exposed to TMT. The effects of the turmeric extract were compared to those of citicoline 
(citidine-5-diphosphocholine or CDP-choline) (an endogenous compound that stabilizes 
membrane function and reduces free radical generation), which is a drug of choice for dementia. 
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2. Methods 
2.1. Animals 
 Thirty-six adult male Sprague Dawley rats weighing approximately 195-215 g were 
obtained from the animal house of Universitas Gadjah Mada. The animals were housed 
individually in cages under standard conditions (room temperature: 24–26 °C; humidity: 60–
65%; 12/12-h natural light/dark cycle). The animals had free access to food and water. The rats 
were acclimatized for at least 6 days prior to the study. The experimental protocols and animal 
handling procedures were approved by the Ethics Committee of the Integrated Research and 
Testing Laboratory, Universitas Gadjah Mada (approval number 130/KEC-LPPT/XII/2013). 
2.2. Extraction of the Turmeric Rhizome 
 The turmeric rhizome was obtained from CV. Merapi Farma, Yogyakarta, Indonesia, 
and verified by a botanist from the Department of Biology, Universitas Ahmad Dahlan, 
Yogyakarta, Indonesia. The extract was prepared as follows: five hundred grams of the turmeric 
rhizome powder were macerated in 1.25 L of 96% ethanol (Merck, Darmstat, Germany). The 
maceration was repeated twice, followed by filtration.  The resulting filtrate was concentrated 
using a vacuum rotary evaporator (Heidolph, Germany) under reduced pressure at 40°C. The 
final yield of the turmeric extract was 30.38 % w/w.  The concentration of curcumin that 
represented the major active content of the extract was determined using a TLC scanner 
densitometer (CAMAG, Switzerland) operated at a wavelength of 426 nm. The curcumin level 
obtained was 28.08%. The turmeric rhizome extract was finally dissolved in a sodium-
carboxymethyl cellulose (CMC-Na) solution prior to oral administration to the rats.  
2.3. Experimental Design 
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 The rats were randomly divided into six groups as follows: the N group served as a normal 
or vehicle group and was treated with the CMC-Na solution (the vehicle of turmeric extract) and 
an intraperitoneal injection of 0.9% saline;  the T group served as control group and was orally 
administered the CMC-Na solution and intraperitoneally injected with TMT chloride (Sigma-
Aldrich, Inc., St. Louis, USA) dissolved in 0.9% saline [11]; the T-Cit group served as a positive 
control group and was orally administered 200 mg/kg bw of a citicoline solution (Bernofarm 
Pharmaceutical Company, Indonesia) and injected with TMT chloride; and  the T-TE100, T-
TE200, and T-TE300 groups, which were orally administered 100 mg/kg bw, 200 mg/kg bw, and 
300 mg/kg bw, respectively, of the ethanolic extract of turmeric and intraperitoneally injected 
with TMT chloride. The doses of the extract adopted in the present study referred to the 
curcumin doses applied in Awasthi et al.’s study [12]. The curcumin doses were converted into 
turmeric extract doses which were considered acceptable for humans. Each group consisted of 
six rats. The ethanolic extracts of turmeric and the citicoline solutions were administered daily 
from day 1 to day 28 of the experiment. The TMT chloride injection was administered as a single 
dose of 8 mg/kg bw on day 8 of the experiment. The turmeric extracts and the citicoline solutions 
were deliberately administered daily for a week prior to the TMT injection with the purpose to 
give a prophylactic protection to the rats. At day 36, the rats’ blood was taken from the sinus 
orbitalis. These blood samples were used to determine the plasma MDA levels. Then, all rats 
were sacrificed and the cerebral hemispheres of the rats were dissected from their skulls. The left 
cerebral hemispheres were homogenized at 4C using a homogenizer (Potter-Elvehjem Tissue 
Grinders, Wheaton, USA). The homogenates were used for the biochemical assays. In the 
present study the cerebral hemispheres were used for the experiment since in the brain of AD 
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patients, oxidative stress products are found not only in the hippocampus but also in other 
regions of the brain such as in the temporal lobe [13].  
2.4. Experimental Procedures 
2.4.1. Measurement of the Plasma Malondialdehyde (MDA) Levels 
 The plasma MDA levels were measured using a previously described method [14]. 
Briefly, 0.75 mL of phosphoric acid was poured into a tube filled with 0.25 mL of thiobarbituric 
acid (TBA) (Sigma Aldrich, Inc., St. Louis, USA).  Subsequently, 0.05 mL of the blood plasma 
and 0.45 mL of water were added to the tube, and this mixture was blended with a vortex for 2 
minutes. The mixture was then heated in a water bath (Memmert, Germany) for 60 minutes at 
60°C. After being cooled for 1-2 hours, the mixture was poured into a Sep-Pak C18 (Waters) 
column to bind with MDA, and washed with 5 mL of methanol and water. The absorbance of the 
mixture was examined using a spectrophotometer (Shimadzu - 1601, Japan) at a wavelength of 
532 nm. The absorbance of the mixture was compared with that of a 1,1,3,3 - tetraethoxypropane 
(TEP) solution (Sigma Aldrich, Inc., St. Louis, USA), which served as a standard. The MDA 
values were expressed as mmol/L plasma. 
 
2.4.2. Measurement of the Brain MDA Levels 
 The brain MDA levels were determined according to the method described in the study 
by Colado et al. [15]. Five hundred microliters of the tissue homogenate dissolved in phosphate 
buffer solution (pH 7.4) were mixed with 300 μL of 30% trichloroacetic acid (TCA), 150 μL of 5 
N HCl, and 300 μL of 2% w/v TBA. The mixture was heated at 90°C for 15 min and centrifuged 
at 12,000 g for 10 min. The absorbance of the supernatant was read in a spectrophotometer at a 
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wavelength of 532 nm. 1,1,3,3-tetraethoxypropane was used as a standard. The MDA level was 
expressed as nmol/mg tissue. 
 
2.4.3 Measurement of the Brain Superoxide Dismutase (SOD) Activity 
The SOD activity in the brain tissues was determined using an Assay Kit, Cat. K335 -100 
(BioVision, USA). The tissues were homogenized in 0.2 mL of 0.1 M Tris/0.1 M HCl (pH 7.4) 
and centrifuged at 14.000 rpm for 5 min at 4°C. The supernatants of these mixtures were used to 
measure the activity of the SOD enzyme. Three blank solution wells were used for each sample.  
Twenty microliters of supernatant were added into the sample well and blank well 2. Meanwhile, 
20 µL of distilled water were added into blank wells 1 and 3. At the same time, 200 µL of 
working solution were added to each well and 20 µL of buffer solution  were added to blank 
wells 2 and 3.  Twenty microliters of the enzyme solution was added into each of the wells and 
the mixture was homogenized by wrapping the microplate with aluminum foil and shaking it. 
These mixtures were then incubated at 37°C for 20 min. The absorbance of these mixtures was 
measured at a wavelength of 450 nm using a microplate reader (Bio Rad model 680 XR, USA). 
The SOD activity was normalized to the milligrams of protein used in the assay and expressed as 
ng/mg protein. 
 
2.4.4. Measurement of the Brain Catalase (CAT) Activity 
The CAT enzyme activity in the tissues was determined using an Assay Kit, Cat. K773-
100 (BioVision, USA). In this assay, catalase first reacts with H2O2 to produce water and 
oxygen. The unconverted H2O2 reacts with an OxiRed™ probe to produce water and oxygen. 
This reaction is assessed by a colorimetric method. Briefly, the brain tissue homogenates were 
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centrifuged at 10.000 rpm for 15 min at 4°C in cold assay buffer, and the supernatants were 
collected for the assay. The assay was performed in triplicate using 96-well microplates. The rate 
of H2O2 decomposition was measured at a wavelength of 570 nm in a microplate reader (model 
680 XR, Bio Rad laboratories, USA). One unit of catalase was defined as the amount of enzyme 
needed to decompose 1 μM of H2O2 in 1 min. The CAT activity was normalized to the 
milligrams of protein used in the assay and expressed as mU/mg protein. 
 
2.4.5. Measurement of the Brain Reduced Glutathione (GSH) Levels 
The GSH content of the brain tissues was analyzed using a colorimetric GSH detection 
kit according to the manufacturer’s instructions (Cat. K261-100, BioVision, USA). One hundred 
milligrams of the brain tissue homogenates dissolved in 0.4 mL of glutathione buffer were mixed 
with 100 μL of 5% SSA, and centrifuged at 8,000 rpm for 10 min. The supernatant of the 
mixture was transferred into a fresh tube and used for the glutathione assay. One hundred sixty 
microliters of a reaction mixture containing the NADPH generating mix, glutathione reductase, 
and glutathione reaction buffer was added to 96-well plates and incubated at room temperature 
for 10 min to generate NADPH.  Twenty microliters of either the GSH standard solutions or the 
supernatant was pipetted into the wells, and the plates were incubated at the room temperature 
for 10 min. The GSH concentrations in the sample solutions were calculated using the standard 
glutathione calibration curve and expressed as µg/mg protein. 
2.4.6. Measurement of the Brain Glutathione Peroxidase (GPx) Activity 
The GPx activity was determined using an assay kit (Cat. K762-100, BioVision, USA) 
according to the manufacturer’s instructions. Approximately 0.1 g of the brain tissue 
homogenates dissolved in 0.2 mL cold assay buffer was centrifuged at 10,000 rpm for 15 min at 
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4°C. The supernatant of this mixture was collected and used for the assay. Ten microliters of the 
supernatants were transferred into 96-well plates. Forty microliters of reaction mix (containing 
33 µL of assay buffer, 3 μL of a 40 mM NADPH solution, 2 μL of GR solution and 2 μL of GSH 
solution) were added to the plates to deplete the GSSG in the samples and this mixture was 
incubated for 15 min. Ten microliters of a cumene hydroperoxide solution was added to the 
mixture to start the GPx reaction. The GPx activity was measured at a wavelength of 340 nm at 5 
min and 140 min. The NADPH levels were calculated based on a standard curve. The GPx 
activity was expressed as mU/mg protein. 
 
2.4.7. Estimation of the Brain Protein Concentrations 
The brain protein concentrations were determined using a biuret method.  One hundred 
milligrams of the brain homogenates were mixed with 0.4 mL of distilled water and centrifuged 
at 8.000 rpm for 15 min. Forty microliters of the supernatant of this mixture was pipetted into 
tubes and distilled water was added until the volume of the mixture reached 150 µL. The mixture 
was then mixed with 100 µL of biuret reagent and incubated at the room temperature for 30 min.  
The absorbance of this mixture was measured at a wavelength of 540 nm using a microplate 
reader (model 680 XR, Bio-Rad Laboratories, USA). The protein concentrations were calculated 
based on a standard curve and expressed as mg/mL. 
 
2.5. Statistical Analyses 
All data were tested using the Shapiro-Wilk and Levene tests for the normality and 
homogeneity of the data, respectively. When the data were normally distributed and 
homogenous, the data were analyzed using one-way ANOVA, followed by the post hoc Tukey’s 
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HSD test. When the data were not normally distributed or homogenous, they were analyzed 
using the Kruskal-Wallis test, followed by the Mann-Whitney U test. All data were analyzed 
using SPSS software version 21. The significance level was set at p < 0.05. 
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3. Results 
  Figures 1 – 6 present the data for the plasma MDA and brain MDA and GSH levels, as 
well as the SOD, CAT, and GPx enzyme activities. The injection of a single dose of 8 mg/kg bw 
of TMT in the T group significantly increased the plasma (p = 0.002) and brain MDA (p = 0.002) 
levels and decreased the activities of the SOD (p = 0.004), CAT (p = 0.0001), and GPx (p = 
0.002) enzymes and the level of GSH (p = 0.002) in the brain compared to the N group. 
The administration of 100 mg/kg bw of the ethanolic turmeric extract to the TMT-
injected rats (T-TE100) significantly decreased the plasma MDA levels, but not the brain MDA 
levels. However, this dose of the ethanolic turmeric extract failed to reverse the TMT-induced 
decrease in the activities of the SOD (p = 0.132), CAT (p = 0.466), and GPx (p = 0.310) 
enzymes and GSH levels (p = 0.602) in the rats’ brains.  
The administration of 200 mg/kg bw of the ethanolic turmeric extract to the TMT-
injected rats (T-TE200) significantly decreased the plasma (p = 0.002) and brain (p = 0.002) 
MDA levels. The activities of the SOD, CAT, and GPx enzymes and GSH levels in the brain 
were significantly increased after the administration of 200 mg/kg bw of the ethanolic turmeric 
extract (p = 0.015; p = 0.045; p = 0.015; and p = 0.015, respectively) compared to the T group. 
The administration of 300 mg/kg bw of the turmeric extract decreased the plasma MDA 
levels (p = 0.002), but not the brain MDA levels, in the TMT-injected rats (T-TE300). This dose 
of the ethanolic turmeric extract was not able to prevent the TMT-induced decrease in the SOD, 
CAT, and GPx enzyme activities and GSH levels compared to the T group. 
The administration of 200 mg/kg bw of citicolin to the TMT-injected rats (T-Cit) 
decreased the plasma (p = 0.002) and brain (p = 0.002) MDA levels. The current dose of 
citicoline also significantly increased the activities of the SOD (p = 0.002), CAT (p = 0.006) and 
13 
 
GPx (p = 0.002) enzymes in the rats’ brains compared to the T group. There was no significant 
difference in the GSH levels between the T-Cit and N groups (p = 0.070) or between the T-Cit 
and T groups (p = 0.117) [16]. 
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4. Discussion  
In the present study, we found that rats injected with a single dose of TMT exhibited an 
increase in the plasma and brain MDA levels and a decrease in the activities of antioxidant 
enzymes (SOD, CAT, and GPx) and the levels of a non-enzymatic antioxidant co-factor (GSH). 
TMT is a potent neurotoxicant that can induce severe damage and neuronal death in both the 
human and animal limbic system, particularly in the hippocampus. TMT is currently regarded as 
a useful tool to obtain an animal model of neurodegeneration associated with cognitive 
impairment, such as dementia. However, the precise mechanisms of its effects are not entirely 
clear [17]. In general, it is thought that the toxicity of organotin compounds is related to the 
number and length of the alkyl groups attached to the tin atom. Its toxicity also depends on the 
compound’s affinity for neurons [18]. Previous studies reported that TMT-induced neuronal 
damage was mediated by derivatives of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS). At high concentrations, ROS, such as hydrogen peroxide (H2O2), superoxide 
anion (O2•−) and hydroxyl radical (HO•), can be important mediators of damage to cell 
structures, including peroxidation of lipids, oxidation of proteins, damage to nucleic acids, and 
enzyme inhibition [19]. In hippocampal cells, TMT intoxication increased membrane lipid 
peroxidation, ultimately leading to cell death. This impact of oxidative stress has been found to 
be implicated in a wide range of neurological disorders including stroke, trauma and dementia 
[20]. 
The 200 mg/kg bw dose of the ethanolic turmeric extract has been shown to exert the 
highest efficacy compared to both the lower and higher doses examined in the current study. The 
administration of turmeric extract prior and subsequent to TMT exposure has been shown to 
prevent the brain of rats from oxidative stress. TMT produces delayed toxicity where the most 
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dramatic reduction of pyramidal cell numbers of TMT-treated rats occurs between 14 and 28 
days after TMT injection [21]. In this study the preventive effect of turmeric extract was 
evidenced by the decrease of the plasma and brain MDA levels and by the increase of the CAT, 
GPx, and SOD enzyme activities and GSH levels in the TMT-injected rats. All parameters were 
measured at the end of the experiment.  
It is well known that curcumin, the major compound of the ethanolic turmeric extract, is 
capable of attenuating the production of reactive oxygen species (ROS) and neutralizing harmful 
free radicals such as superoxide anions, hydroxyl radicals and nitric oxide  [22]. The phenolic 
and the methoxy groups on the phenyl ring appear to be important structural features for these 
actions [23]. Curcumin induces endogenous antioxidant defense mechanisms by modulating  
nuclear factors such as  E2-related factor 2 (Nrf2) [24], activator protein-1 (AP-1), and nuclear 
factor kappa B (NF𝜅B). This in turn implicates the expression of a variety of genes in response 
to oxidative stress [25]. Phosphorylation of Nrf2 allows the Nrf2 to translocate to the nucleus and 
bind to the antioxidant response element (ARE) in the regulatory region of the target genes and 
induce the transcription of antioxidant enzymes [26]. 
Pre-clinical studies have shown that orally delivered curcumin has neuroprotective effects  
[27] and has been found to reduce lipid peroxidation by maintaining the activities of antioxidant 
enzymes such as CAT, SOD, GPx and GSH levels in rats exposed with neurotoxic compounds  
[28,29]. The ability of curcumin to increase the GSH levels is due to its affinity to induce the 
transcription of the mRNAs for the GSH biosynthetic genes [30]. Clinical studies also 
demonstrated that oral curcumin remarkably improved the behavioral symptoms of patients with 
Alzheimer’s disease [31] and  ameliorated systemic oxidative stress on human with chronic 
pulmonary complication [32].  
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The particular method of preparation of curcumin may enhance the above-mentioned 
beneficial effects of curcumin. Curcumin emulsified in carboxymethyl cellulose has a potent 
anti-inflammatory effect [33]. Curcumin in its dissolved or emulsified form has been shown to 
be easily absorbed in the gastrointestinal system of rats [34]. Furthermore, curcumin 
administrated orally is considered to cross the blood-brain barrier as shown in a multi-photon 
microscopy study on in vivo Alzheimer’s model of mice [35]. However, in the present study, it 
remains uncertain whether the reconstituted turmeric actually crossed the blood brain barrier, 
since we used turmeric extract instead of curcumin, and applied a different method of dissolution 
from that of Cui et al and Garcia-Alloza et al’s studies [34,35]. Further investigation on the 
pharmacokinetics of turmeric extract is required to determine the bioavailability of curcumin in 
both the brain and plasma. 
The present study did not observe a linear dose-response relationship between the effects 
of the ethanolic turmeric extract on TMT-induced oxidative stress. The higher doses of the 
ethanolic turmeric extract (300 mg/kg bw) did not correspond to increased activity of the extract. 
This may be due to paradoxical effects of curcumin, which can act as an antioxidant or pro-
oxidant, depending on the concentration and the cellular environment [36]. The pro-oxidant 
activities appear to be mediated by the generation of phenoxyl radical of curcumin by the 
peroxidase–H2O2 system, which co-oxidizes cellular glutathione or NADH to form ROS [37]. 
Curcumin-mediated apoptosis is closely related to the increase in the intracellular ROS levels. 
The exact dose of curcumin that can cause the pro-oxidative effects remains to be determined. 
The antioxidant activities of the 200 mg/kg bw dose of the turmeric extract seem to 
resemble those of citicoline in several parameters (plasma and brain MDA levels; SOD, GPx, 
and CAT enzyme activities). Citicoline  is commonly used as a neuroprotective and memory 
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enhancing agent [38]. In this study, this drug was shown to reduce the plasma and brain MDA 
levels, as well as to increase the levels of GSH and the GPx, SOD and CAT enzyme activities in 
the brains of rats exposed to TMT. Another study reported that citicoline stimulated the 
biosynthesis of glutathione, activated the glutathione reductase enzyme, and prevented lipid 
peroxidation [39].   
 In summary, the ethanolic turmeric extract prevented TMT-induced oxidative stress at a 
dose of 200 mg/kg bw by decreasing the plasma and brain MDA levels and increasing the SOD, 
CAT, and GPx enzyme activities as well as GSH levels in the brain. These effects seem to be 
similar to those of citicoline. Further studies are required to investigate the potential use of this 
extract as a substitute treatment for neurodegenative disorders. 
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Figure captions 
 
Figure 1. Comparison of the plasma MDA levels in the normal (N), control TMT (T), Citicolin 
(T-Cit), 100 mg/kg bw of the ethanolic turmeric extract  (T-TE100), 200 mg/kg bw of the 
ethanolic turmeric extract  (T-TE200) and 300 mg/kg bw the ethanolic turmeric extract  (T-
TE300) groups of Sprague Dawley rats exposed to TMT. The values are expressed as the means 
± SEM of each group (n = 6). *p < 0.05, compared to the T group; #p < 0.05, compared to the N 
group; Kruskal-Wallis test, followed by the Mann-Whitney U test.  
 
Figure 2. Comparison of the brain MDA levels in the normal (N), control TMT (T), Citicolin (T-
Cit), 100 mg/kg bw of the ethanolic turmeric extract  (T-TE100), 200 mg/kg bw of the ethanolic 
turmeric extract  (T-TE200) and 300 mg/kg bw of the ethanolic turmeric extract  (T-TE300) 
groups of Sprague Dawley rats exposed to TMT. The values are expressed as the means ± SEM 
of each group (n = 6). *p < 0.05, compared to the T group; #p < 0.05, compared to the N group; 
Kruskal-Wallis test, followed by the Mann-Whitney U test. 
 
Figure 3. Comparison of the brain SOD activity in the normal (N), control TMT (T), Citicolin 
(T-Cit), 100 mg/kg bw of the ethanolic turmeric extract  (T-TE100), 200 mg/kg bw of the 
ethanolic turmeric extract  (T-TE200) and 300 mg/kg bw of the ethanolic turmeric extract  (T-
TE300) groups of Sprague Dawley rats exposed to TMT. The values are expressed as the means 
± SEM of each group (n = 6). *p < 0.05, compared to the T group; #p < 0.05, compared to the N 
group; Kruskal-Wallis test, followed by the Mann-Whitney U test. 
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Figure 4. Comparison of the brain catalase activity in the normal (N), control TMT (T), Citicolin 
(T-Cit), 100 mg/kg bw of the ethanolic turmeric extract  (T-TE100), 200 mg/kg bw of the 
ethanolic turmeric extract  (T-TE200) and 300 mg/kg bw of ethanolic turmeric extract  (T-
TE300) groups of Sprague Dawley rats exposed to TMT. The values are expressed as the means 
± SEM of each group (n = 6). *p < 0.05, compared to the T group; #p < 0.05, compared to the N 
group; one-way ANOVA test, followed by Tukey’s HSD test.  
F5, 30 = 7.533; p <0.05 
 
Figure  5. Comparison of the brain GSH levels in the normal (N), control TMT (T), Citicolin (T-
Cit), 100 mg/kg bw of the ethanolic turmeric extract  (T-TE100), 200 mg/kg bw of the ethanolic 
turmeric extract  (T-TE200) and 300 mg/kg bw of the ethanolic turmeric extract  (T-TE300) 
groups of Sprague Dawley rats exposed to TMT. The values are expressed as the means ± SEM 
of each group (n = 6). *p < 0.05, compared to the T group; #p < 0.05, compared to the N group; 
one-way ANOVA, followed by Tukey’s HSD test. 
F5, 30 = 4.214; p < 0.05 
 
Figure 6. Comparison of the GPx activity in the normal (N), control TMT (T), Citicolin (T-Cit), 
100 mg/kg bw of the ethanolic turmeric extract  (T-TE100), 200 mg/kg bw of the ethanolic 
turmeric extract  (T-TE200) and 300 mg/kg bw of the ethanolic turmeric extract  (T-TE300) 
groups of Sprague Dawley rats exposed to TMT. The values are expressed as the means ± SEM 
of each group (n = 6). *p < 0.05, compared to the T group; #p < 0.05, compared to the N group; 
Kruskal-Wallis test, followed by the Mann-Whitney U test. 
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